In contrast, over a median follow-up of 7 months, Patorno et al. 105 reported a lower relative risk of myocardial infarction with SGLT2i compared to GLP1-RA in US claims data specific to individuals with a history of CVD (n=156,825; HR 0.83 [95%CI 0.74, 0.93] with history of CVD; HR 1.13 [95%CI 1.00, 1.28] without history of CVD), with no differences in stroke outcomes irrespective of CVD status. The gene discussed is GLP1R; the disease is myocardial infarction.